Fed. Circ. Says Tribal Immunity Doesn't Apply In IPR

Law360 (July 20, 2018, 11:55 AM EDT) -- The Federal Circuit on Friday ruled tribal sovereign immunity doesn’t apply in reviews at the Patent Trial and Appeal Board, rejecting an attempt from Allergan PLC to shield patents for its dry-eye medication Restasis by transferring them to a Native American tribe.

​Drugmaker Allergan suffered a setback when the Federal Circuit ruled that it could not transfer patents to a Native American tribe to shield them from review. (AP)

The appeals court, in a precedential opinion, affirmed the PTAB’s decision that it has the authority to decide the validity of several patents that were challenged by generic drug companies and are...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS